CN Patent

CN110960525A — 新型eed-ezh2相互作用抑制剂的确定和评价

Assigned to University of Jinan · Expires 2020-04-07 · 6y expired

What this patent protects

本发明涉及图1所示的化合物49作为EED‑EZH2相互作用的小分子抑制剂的用途，及其在制备预防和/或治疗恶性淋巴瘤的药物中的用途。所述恶性淋巴瘤为弥漫性大B细胞淋巴瘤相关的疾病。

USPTO Abstract

本发明涉及图1所示的化合物49作为EED‑EZH2相互作用的小分子抑制剂的用途，及其在制备预防和/或治疗恶性淋巴瘤的药物中的用途。所述恶性淋巴瘤为弥漫性大B细胞淋巴瘤相关的疾病。

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: CN110960525A
Jurisdiction: CN
Classification: —
Expires: 2020-04-07
Drug substance claim: No
Drug product claim: No
Assignee: University of Jinan
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.